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Summary Low density lipoprotein (LDL-C) levels de-
termine the cardiovascular risk. Previous studies indi-
cated an LDL-C target attainment of around 50 %, but 
no Austrian wide analysis on results for the federal states 
was available. We therefore sought to detect potential 
differences.
Design: Open-label, non-interventional, longitudinal 
study, registered: www.clinicaltrials.gov NCT 01381679. 
In all, 746 statin treated patients not at LDL-C goal re-
ceived intensified therapy for 12 months. The sample 
was split into nine subgroups, representing the federal 
states of Austria.
Wien Med Wochenschr (2013) 163:528–535
DOI 10.1007/s10354-013-0219-z
Are there differences in LDL-C target value 
attainment in Austrian federal states? Yes!
Max Pichler · Dominik Lautsch · Claudia Adler · Karl Bögl · Heinz Drexel · 
Bernd Eber · Christiane Fauer · Johannes Föchterle · Bernhard Föger · Karin Gansch · 
Peter Grafinger · Monika Lechleitner · Bernhard Ludvik · Gerald Maurer · Reinhard Mörz · 
Bernhard Paulweber · Karl Peter Pfeiffer · Rudolf Prager · Gerhard Stark · 
Hermann Toplak · Otto Traindl · Raimund Weitgasser
Received: 22 February 2013 / Accepted: 27 May 2013 / Published online: 27 August 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com 
The Austrian cholesterol screening and treatment II (ACT II) 
study group.
Dr. D. Lautsch, MS () · 
o.Univ. Prof. Dr. Dr. h.c. H. Drexel 
Private University of the Principality of Liechtenstein, 
Dorfstrasse 24, 9495 Triesen, Liechtenstein
e-mail: dominik.lautsch@merck.com
Dr. D. Lautsch, MS · Dr. C. Adler, MS, MBA ·  
DDr. K. Bögl, MBA · C. Fauer, MS · K. Gansch
Merck Sharp & Dohme, Am Europlatz 2, 1120 Wien, Austria
Univ. Prof. Dr. M. Pichler · Univ. Doz. Dr. B. Paulweber
Paracelsus Medical University, Salzburg, Austria
o.Univ. Prof. Dr. Dr. h.c. H. Drexel
Vorarlberg Institute for Vascular Investigation and Treatment 
(VIVIT), Feldkirch, Austria
Univ. Prof. Dr. B. Eber





Landeskrankenhaus Bregenz, Bregenz, Austria
Dr. P. Grafinger
General Hospital Linz, Linz, Austria
Univ. Prof. Dr. M. Lechleitner
Landeskrankenhaus Hochzirl, Anna Dengel-Haus, Zirl, Austria
Univ. Prof. Dr. B. Ludvik
Department of Internal Medicine III, Medical University of Vienna, 
Vienna, Austria
o.Univ. Prof. Dr. G. Maurer
Department of Internal Medicine II, Division of Cardiology, 
Medical University of Vienna, Vienna, Austria
Dr. R. Mörz
Vienna, Austria
Univ. Prof. DI. Dr. K. P.  Pfeiffer
Joanneum, University of Applied Sciences, Graz, Austria
Univ. Prof. Dr. R. Prager
Hospital Hietzing, Vienna, Austria
Univ. Prof. Dr. R. Prager
KLI für Stoffwechselerkrankungen, Vienna, Austria
Univ. Prof. Dr. G. Stark
Krankenhaus der Elisabethinen, Graz, Austria
Univ. Prof. Dr. H. Toplak
Medical University of Graz, Graz, Austria
Univ. Doz. Dr. O. Traindl
Landesklinikum Weinviertel, Mistelbach, Austria
Univ. Doz. Dr. R. Weitgasser
Abteilung für Innere Medizin, Diakonissen-Krankenhaus Salzburg, 
Salzburg, Austria
original article
1 3 Are there differences in LDL-C target value attainment in Austrian federal states? Yes!  529
We detected an east-west gradient for baseline LDL-
C. Individual target values were achieved by 37.2 % 
(range: 26.1–57.7 %). After 12 months, LDL-C < 70  mg/l 
was achieved by 13.5 % (5.9–38.5 %). Univariate AN-
COVA retrieved significant differences within the states 
(Upper Austria and Salzburg, p = 0.001 and p = 0.0015, 
respectively). Furthermore, the capacity of intensified 
lipid lowering therapy applied in practice was as high as 
−42 % as compared to previous standard therapy (addi-
tional LDL-C reduction after switch from baseline therapy 
in Vorarlberg).
Keywords LDL Cholesterol · Regional differences · 
Ezetimibe · Statin · Coronary Heart Disease
Gibt es Unterschiede in der LDL-Cholesterin 
Zielwerterreichung zwischen den Österreichischen 
Bundesländern? Ja! 
Zusammenfassung Low Density Lipoprotein Choleste-
rin (LDL-C) Spiegel determinieren das kardiovaskuläre 
Risiko. Vorangegangene Studien zeigten eine LDL-C 
Zielwerterreichung von circa 50 %. Nachdem keine ös-
terreichweite geographische Analyse zur Zielwerterrei-
chung verfügbar war, ermittelten wir, ob es Unterschie-
de zwischen den Österreichischen Bundesländern gibt.
Design: Open-label, nicht-interventionelle, longitu-
dinale Studie, registriert unter www.clinicaltrials.gov 
NCT01381679. 746 statinbehandelte Patienten, die ihren 
LDL-C Zielwert nicht erreichten, erhielten intensivierte 
Therapie. Die Stichprobe wurde in neun, die Österrei-
chischen Bundesländer repräsentierenden, Subgruppen 
unterteilt.
Ein Ost-West Gradient konnte für LDL-C zu Beginn 
der Studie festgestellt werden. LDL-C Werte <70  mg/dl 
wurden von 13,5 % (5,9–38,5 %) der Patienten in Öster-
reich nach 12 Monaten erreicht. Univariate ANCOVA 
zeigte einen signifikanten Unterschied zwischen den 
Bundesländern (Oberösterreich und Salzburg, p = 0,001, 
bzw. p = 0,0015). Die Kapazität intensivierter, in der Pra-
xis angewandter, lipidsenkender Therapie betrug −42 % 
im Vergleich zu vorhergehender Standardtherapie (zu-
sätzliche LDL-C Senkung nach Switch von der Therapie 
zu Beginn der Studie in Vorarlberg).
Schlüsselwörter LDL Cholesterin · Regionale Unter-
schiede · Ezetimib · Statin · Koronare Herzkrankheit
Introduction
Elevated cholesterol levels are a paramount risk factor for 
the development of atherothrombotic events and even-
tually cardiovascular death [1, 2]. Reaching low density 
lipoprotein cholesterol (LDL-C) target values can reduce 
the incident of such events: According to the data of 
the CTT meta-analysis, a 1  mmol/L (around 39  mg/dl) 
reduction in LDL-C levels resulted in a 22 % reduction 
of cardiovascular events and a 10 % reduction of total 
mortality [3]. Furthermore, evidence from statin, niacin, 
and ezetimibe studies supports that achieved LDL-C lev-
els < 80 mg/dl can lead to a regression in atheroma vol-
ume [4–6]. Both international and Austrian guidelines 
recommend LDL-C levels between 70 and 100 mg/dl for 
patients at high or very high cardiovascular risk [7–9]. The 
most recent European guidelines recommend a target 
value of 70 mg/dl for virtually all patients with coronary 
heart disease or diabetes [8, 9]. Previous cross-sectional 
studies revealed a target attainment of around 50 % in 
high-risk patients not only in Austria, but all over the 
western world [10–15].
We acknowledge the interesting, recently published 
data on geographical differences within Austria for both 
obesity and cardiovascular mortality [16, 17]. These dif-
ferences were associated with gradients in diabetes mel-
litus and hypertension and explained by psychosocial 
differences that apply to the highly populated, urban 
eastern Austrian region versus the rural, mountainous 
west. Furthermore and according to the authors of those 
studies, the level of education is lower in eastern Austria 
than in the rest of the country. In order to see whether 
such differences also exist concerning hyperlipidemia, 
baseline LDL-C and target value attainment, we aimed 
to asses geographical aspects within Austria, especially 
considering differences between the nine federal states.
Patients, material and methods
The detailed study design of the Austrian cholesterol 
screening and treatment II (ACT II) study was published 
elsewhere [18]. In brief, the present paper refers to a 
population-based, open-label, non-interventional, and 
observational longitudinal study. Study centers were 
office based internists and family care physicians who 
consecutively included patients at high or very high 
cardiovascular risk on statin therapy and not reaching 
LDL-C target levels. Subsequently, they received intensi-
fied cholesterol reducing therapy at the discretion of the 
treating physicians in order to reach individual LDL-C 
targets. After baseline examination two follow-up visits 
were performed after 3 and 12 months.
Study period was 12 months. The study was performed 
between 2009 and 2010.
In order to detect differences in LDL-C target achieve-
ment, the sample was split into nine distinct groups rep-
resenting the federal states Burgenland, Carinthia, Lower 
Austria, Upper Austria, Salzburg, Styria, Tyrol, Vorarl-
berg, and Vienna. The patients included represent 0.01 % 
of each state’s population, Table 1 [19].
The present substudy aims to detect differences in 
LDL-C target attainment after 12 months of intensified 
medical therapy in the nine Austrian federal states. Ref-
erence for LDL-C targets were the former guidelines on 
cardiovascular disease prevention, issued by the Euro-
pean Society for Cardiology in 2007 [20] and the National 
Cholesterol Education Program Adult Treatment Panel III 
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(NCEP ATP III) guidelines [21], which were valid and effec-
tive during the study. At the time of examination, LDL-C 
target value <70 mg/dl was in place only for patients suf-
fering from concomitant coronary heart disease (CHD) 
and diabetes (DM) or metabolic syndrome, acute coro-
nary syndrome (ACS) or progressive heart disease. Target 
value <100 mg/dl was in place for patients diagnosed with 
CHD (only), Type 2 DM, Type 1 DM and nephropathy, 
extracoronary atherosclerosis, or an ESC SCORE <5 %. As 
mentioned, the most recent guidelines set LDL-C  <70 mg/
dl as the target value for all of these patients, reflecting cur-
rent evidence from large outcome trials.
Adult, statin treated patients who did not meet LDL-C 
target values were included in the study. This selection 
of patients was based on the Austrian reimbursement 
rules in order to reflect practice conditions in this non-
interventional study. Austrian reimbursement rules are 
defined by the Erstattungskodex (EKO, local reimburse-
ment compendium) [22]. Exclusion criteria were contra-
indications to any of the drugs used in the course of the 
non-interventional study and an age <18 years.
LDL-C was calculated using the Friedewald For-
mula in standardized Austrian medical labs. Statistical 
calculations were performed with SPSS 17.0. For com-
parisons between the states we used ANOVA, for regres-
sion analyses univariate models in a stepwise approach 
(ANCOVA), as further explained in the result section. Val-
ues were collected using paper based case report forms, 
the electronic transfer was performed by the Koordinier-
ungszentrum für Klinische Studien, Medical University 
Innsbruck. No missing values were added post hoc or 
calculated by regression to the mean nor supplemented 
by other methods. Adverse events were documented pre-
cisely and coded according to MedDRA Version 13.1.
The study was approved by the institutional review 
boards and presented to the Leit-Ethikkomission der 
Stadt Wien (ethics commission). The 1964 Declaration 
of Helsinki was fully respected. Patients gave consent to 
the documentation of their anonymized data, treating 
doctors acted as responsible parties. Registration: www.
clinicaltrails.gov registration number NCT 01381679.
Results
The study included patients from all nine Austrian federal 
states. While 1,682 patients were included in the study, a 
complete record of the three examinations (baseline, fol-
low-up 1 and follow-up 2) and allocation of the center to 
a federal state is available for 746 Patients, treated in 389 
centers (GP and internists offices). The results focus only 
on these 746 patients. Distribution over the nine Aus-
trian states was as followed: Burgenland n = 16, Carinthia 
n = 36, Lower Austria n = 213, Upper Austria n = 88, Salz-
burg n = 27, Styria n =164, Tyrol n = 69, Vorarlberg n = 20, 
Vienna n = 113.
At baseline and for Austria, the distribution of the 
major lipid parameters was as follows: mean LDL-C 
was 145 ± 35 mg/dl (all values given are means  standard 
deviation, SD), total cholesterol 236 ± 45  mg/dl, HDL-C 
50 ± 15  mg/dl, and triglycerides were 198  ± 120  mg/dl. 
There were no significant differences within the states 
with the exception of HDL cholesterol where differ-
ences were highly significant at p = 0.0001, Table 2. With 
regard to body weight and waist circumference, data 
ranged from 77 ± 12 kg (Vorarlberg) to 85 ± 14 kg (Carin-
thia), and 99 ± 12 cm (Vorarlberg) to 102 ± 14 cm (Lower 
Austria), respectively. Those differences were significant 
(p = 0.001, Table 3).
Mean LDL-C dropped from the baseline value 
145 ± 35  mg/dl to 95 ± 26  mg/dl after 12 months ther-
apy. Values ranged from 130 ± 25  mg/dl (Salzburg) to 
163 ± 43  mg/dl (Burgenland) at baseline (differences 
between states not significant; Table  2). At follow up 
visit 1 LDL-C dropped to 89 ± 22  mg/dl (Salzburg) to 
117 ± 37  mg/dl (Burgenland) and at follow-up visit 2 to 
84  ±  20  mg/dl (Salzburg) to 107 ± 26  mg/dl (Carinthia). 
While no significant differences could be detected at 
baseline and at follow-up visit 1, differences in the sec-
ond follow-up visit were highly significant at p = 0.005 
(ANOVA). For further details please refer to Table 2.
In all, 44.6 % of the patients could be classified as 
patients at highest cardiovascular risk and 55.4 % as 
patients at high cardiovascular risk (both groups would 
be considered to be at very high cardiovascular risk in the 
recent ESC/EAS guidelines on dyslipidemias) Target val-
ues were then defined as <70 and <100 mg/dl respectively. 
While these individual targets were achieved in 37.2 % of 
the population, we found differences in target attain-
ment within the nine federal states: Data ranged from 
26.1 % (Vienna) to 57.7 % (Salzburg). Values above the 
median of 39.0 % were achieved in Burgenland (53.3 %), 
Upper Austria (40.9 %), Salzburg (57.7 %), and Vorarl-
berg (40.0 %),. LDL-C levels <100 mg/dl were reached by 
60.8 % of all Austrian patients at follow-up visit 2. There 
is a high variance between the Austrian federal states, 
ranging from 38.2 % (Carinthia) to 76.9 % (Salzburg).
Most important, LDL-C levels <70  mg/dl (the cur-
rent standard targets for these groups of patients) were 
attained by 13.5 % of the Austrian sample with an analo-
gous variance for the states ranging from 5.9 % (Carin-
thia) to 38.5 % (Salzburg). Details are displayed in Fig. 1.
An analysis of covariance (ANCOVA) was performed 
in a stepwise approach in order to test the influence of 
Table 1 Patient numbers in the study in comparison to the states’ population
Austria Burgenland Carinthia Lower Austria Upper Austria Salzburg Styria Tyrol Vorarlberg Wien
Public census 8,281,295 280,082 559,698 1,587,651 1,403,762 525,859 1,203,036 696,049 363,952 1,661,206
Inclusion in ACT II 746 16 36 213 88 27 164 69 20 113
Percentage (%) 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
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the possibly relevant, examined parameters weight, age, 
waist circumference, systolic and diastolic blood pres-
sure, as well as body mass index (dependent variable 
of ANCOVA were the achieved LDL-cholesterol values 
in follow-up visits 1 and 2). For the baseline LDL-C val-
ues, we could retrieve an influence of weight (regression 
co-efficient beta −0.62, p = 0.001), waist circumference 
(regression co-efficient beta −0.62, p = 0.001) and age 
(regression co-efficient beta −0.62, p = 0.001) only. There 
was no significant influence by the federal states them-
selves but we observed a positive trend (towards high 
LDL-C levels) for Burgenland (p = 0.051) and a negative 
trend (towards low LDL-C levels) for Salzburg (p = 0.052).
According to these results we then performed a uni-
variate analysis of covariance including the federal states, 
weight, age, and body circumference only. While results 
for baseline LDL-C levels did not change in a meaning-
ful way, we could determine an influence of age only at 
follow-up visit 1 after 3 months (regression co-efficient 
beta −0.31, p = 0.01) but not after 12 months. At this stage, 
we detected a significant influence of the federal state of 
Salzburg (p = 0.006). After 12 months and considering fol-
low-up visit 2, none of the remaining parameters weight, 
waist circumference, or age had a statistically significant 
or trend wise influence on LDL-C levels (p = 0.29, p = 0.58, 
and p = 0.09). Three federal states remained indepen-
Table 3 Parameters at baseline in respect to the nine Austrian federal states
Body weight (kg) Waist circumference (cm) SysBP (mmHg) DiaBP (mmHg) Age (years)
Burgenland 84  ±  18 101  ±  14 138  ±  15 84  ±  9 64  ±  9
Carinthia 85  ±  14 101  ±  11 135  ±  13 83  ±  7 60  ±  10
Lower Austria 84  ±  14 102  ±  14 136  ±  15 80  ±  9 64  ±  10
Upper Austria 83  ±  14 96  ±  13 136  ±  14 82  ±  8 64  ±  10
Salzburg 79  ±  16 99  ±  17 135  ±  18 81  ±  10 66  ±  11
Styria 82  ±  14 99  ±  11 135  ±  15 81  ±  9 64  ±  11
Tyrol 79  ±  14 101  ±  12 133  ±  16 81  ±  9 66  ±  10
Vorarlberg 77  ±  12 99  ±  12 136  ±  11 82  ±  9 64  ±  11
Vienna 82  ±  16 101  ±  13 136  ±  15 81  ±  9 62  ±  11
Austria 82  ±  15 100  ±  13 136  ±  15 81  ±  9 64  ±  10
Differences between the states 0.001 0.0001 n.s. (0.457) n.s. (0.110) 0.0001
SysBP Sitting systolic blood pressure, DiaBP Sitting diastolic blood pressure; all values given as mean ± SD
Table 2 Parameters at baseline in nine Austrian federal states
Total cholesterol (mg/dl) LDL Cholesterol (mg/dl) HDL Cholesterol (mg/dl) Triglycerides (mg/dl)
Baseline FU 1 FU 2 Baseline FU 1 FU 2 Baseline FU 1 FU 2 Baseline FU 1 FU 2
Burgenland 
(n  =  16)
262  ±  60 209  ±  53 204  ±  77 163  ±  43 117  ±  37 96  ±  24 67  ±  28 59  ±  25 65  ±  26 147  ±  78 145  ±  62 135  ±  58
Carinthia 
(n  =  36)
245  ±  51 197  ±  54 194  ±  42 146  ±  37 102  ±  35 107  ±  26 45  ±  11 48  ±  12 50  ±  13 234  ±  141 193  ±  102 161  ±  56
Lower Austria 
(n  =  213)
233  ±  45 188  ±  38 181  ±  35 146  ±  34 104  ±  31 95  ±  28 48  ±  12 50  ±  13 52  ±  13 205  ±  127 164  ±  93 149  ±  73
Upper Austria 
(n  =  88)
230  ±  46 186  ±  49 174  ±  36 140  ±  33 97  ±  32 88  ±  26 52  ±  15 56  ±  15 56  ±  15 180  ±  87 168  ±  74 160  ±  80
Salzburg 
(n  =  27)
229  ±  44 181  ±  42 172  ±  27 130  ±  25 89  ±  22 84  ±  20 54  ±  13 58  ±  17 57  ±  14 181  ±  78 152  ±  65 159  ±  88
Styria 
(n  =  164)
240  ±  46 188  ±  36 179  ±  38 148  ±  34 103  ±  33 97  ±  26 50  ±  14 54  ±  14 54  ±  15 191  ±  112 158  ±  69 153  ±  81
Tyrol (n  =  69) 231  ±  36 190  ±  29 182  ±  24 140  ±  38 106  ±  25 96  ±  21 50  ±  13 52  ±  12 56  ±  18 188  ±  98 159  ±  55 153  ±  66
Vorarlberg 
(n  =  20)
235  ±  40 184  ±  30 176  ±  32 154  ±  37 100  ±  30 90  ±  24 50  ±  18 52  ±  11 57  ±  15 178  ±  61 159  ±  45 150  ±  38
VIenna 
(n  =  113)
238  ±  41 194  ±  41 185  ±  36 144  ±  34 107  ±  35 99  ±  27 48  ±  16 51  ±  15 51  ±  16 221  ±  157 173  ±  91 161  ±  74
Austria 
(n  =  746)


















FU 1 follow-up visit 1, 3 months after baseline, FU 2 follow-up visit 2, 12 months after baseline, n.s. statistically not significant; all values given as mean ± SD
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dently and statistically significant strongly associated 
with the achieved LDL-C values: Carinthia (regression 
co-efficient beta 11.43, p = 0.024), Upper Austria (regres-
sion co-efficient beta −9.88, p = 0.01), and Salzburg 
(regression co-efficient beta −16.25, p = 0.004).
To further validate the results we looked at the influ-
ence of baseline LDL-C levels on target attainment at 
follow-up visits 1 and 2. After 3 months the effect was 
highly relevant and significant (regression co-efficient 
beta 0.42, p < 0.001) but decreased—still significant—to 
0.22 (p < 0.001) after 12 months. Even after inclusion of 
this strong parameter, baseline LDL-C, two federal states 
remained to have the described, very strong influence on 
LDL-C levels: Upper Austria (regression co-efficient beta 
− 9.40, p = 0.01) and Salzburg (regression co-efficient beta 
− 13.14, p = 0.015), while a positive trend was observed for 
Carinthia (regression co-efficient beta 8.65, p = 0.07).
Lipid therapy at baseline was, as previously reported 
[18], Simvastatin 62 %, Atorvastatin 10 %, Fluvastatin 8 %, 
Lovastatin 1 %, Pravastatin 9 %, Rosuvastatin 6 %, and any 
other therapy at 4 %. During the study, primarily Ezeti-
mibe/Simvastatin fixed dose combinations were used 
(10/20 mg as most widely use dosage: 45–81 %, least value 
in Vienna, highest one in Salzburg). Statins in mono-
therapy (between 0–13 % per state) were administered 
at intermediate doses. No significant differences in the 
treatment regimens between the Austrian federal states 
could be detected.
The documentation of adverse events includes three 
serious adverse events under fixed dose ezetimibe simv-
astatin combination therapy. They were not related to the 
lipid lowering therapy administered. A detailed assess-
ment was published elsewhere [18].
Discussion
We report significant differences in attaining the LDL-C 
target value <70  mg/dl between Austrian states rang-
ing from 5.9–38.5 %. We could further identify an east 
to west gradient in Austria with highest LDL-C baseline 
levels in the east and lowest in the west (Fig. 2, excep-
tion Vorarlberg). Such a gradient was recently similarly 
shown for obesity and cardiovascular mortality [16, 17]. 
Higher LDL-C levels at baseline were documented in 
Vorarlberg, a region (specifically the Rhine valley) simi-
larly industrialized as the areas surrounding the capital 
city Vienna.
Therapy in this non-interventional study was intensi-
fied lipid lowering treatment at the discretion of the phy-
sician. The INCROSS [23] study looked at a population 
treated with statins and not at goal value and compared 
Rosuvastatin 10 mg to Ezetimibe/Simvastatin 10/20 mg, 
the therapy most often used (57 %) in this study. While 
Rosuvastatin 10 mg achieved a −17 % LDL-C reduction, 
this value was significantly improved by Ezetimibe/Sim-
vastatin to −28 %. In a very similar approach, a −29 % 
reduction could be achieved after switching patients 
from Simvastatin 20  mg or Atorvastatin 10  mg to Ezeti-
mibe/Simvastatin 10/20  mg in the EASEGO study [24]. 
Several studies [25–27] reported a − 20 to − 27 % LDL-C 
decrease for Ezetimibe, while LDL-C was lowered by 
−49 % with Rosuvastatin 20 mg and by −42 % by Atorvas-
tatin in the important trials JUPITER [28] and PROVE-IT 
TIMI 22 [29]. The Treating to New Targets trial [30], com-
paring high dose Atorvastatin 80  mg vs. standard dose 
Atorvastatin 10 mg, retrieved a −21 % reduction for 80 vs 
10 mg which is comparable to the results of the VOYAGER 
Fig. 1 Attainment of low density lipoprotein cholesterol values <70 mg/dl (current target value as set by the major European 
societies) after 12 months
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meta-analysis that showed a −5 to −6 % LDL-C reduction 
for each statin titration step [31]. In comparison to these 
clinical data, our results show what was achieved in prac-
tice: mean was −31 % [18], however looking at a federal 
state level this value was improved up to −42 % (Vorarl-
berg) and −41 % (Burgenland). At the end of the day, the 
achieved reductions always depend on three factors: the 
therapy administered, the willingness of the treating phy-
sicians to accept new target levels (< 70  mg/dl for most 
patients in secondary prevention [8, 9]) and the patients 
compliance. As for pharmacological lipid therapy, the 
highest tolerated dose of statin therapy in combination 
with drugs such as ezetimibe is efficacious and should be 
used in order to reach LDL-C target levels as according to 
the guidelines [8].
Looking at achieved absolute LDL-C reductions, data 
range from − 39 to −67 mg/dl or 1 to 1.5 mmol/l. Apply-
ing data from the CTT meta-analysis [3] in practice this 
would equal to a 22–38 % reduction in cardiovascular 
events with Carinthia at the lower and Vorarlberg and 
Burgenland at the higher end (s. Table 2). The CTT analy-
sis was performed with statin trials only, but the recent 
publication of the SHARP trial [32] indicated, these data 
should also apply to the statin ezetimibe combination 
therapy.
Fully applying the LDL-C target of <70  mg/dl target 
and thus implementing the EAS/ESC 2011 guidelines [8], 
roughly one-third of the population in Salzburg reached 
these targets while this value decreased for Carinthia to 
only 6 % (where only one-third of the population reaches 
the <100  mg/dl threshold). Interestingly, greatest car-
diovascular mortality was reported for Burgenland and 
Vienna with Tyrol, Carinthia and Vorarlberg as states 
of lowest cardiovascular mortality risk [17]. Of notice, 
Vienna was the state with notably low target attainment 
in the present study.
The observed differences between the federal states 
are puzzling and hard to understand. Even though num-
bers of patients are not equal for each state, the same per-
centage of the broad population was included (0.01 %). 
We could describe differences in baseline LDL-C which 
can explain the results to some extent, but Salzburg 
and Upper Austria were independently associated with 
improved target value attainment. At this point we can 
only postulate about different doctor-patient relation-
ship or compliance, but this raises more questions than 
we could answer from the data provided in this non-
interventional study.
Limitations of the study were due to its observational 
rather than interventional, endpoint-driven nature and 
due to varying patient numbers in the respective Aus-
trian states. In Burgenland, Carinthia, Salzburg, and 
Vorarlberg, less than 60 patients were included. These are 
comparable small numbers, but we included 0.01 % of 
the populations in all nine Austrian states (Table 1). Yet, 
the observational nature should be taken as the strength 
of this study: it reflects real life and thus shows important 
and interesting differences within the regions of Austria, 
a small but highly heterogeneous country.
In conclusion, the Austrian analysis of the ACT II study 
revealed high differences between the nine Austrian fed-
eral states in LDL-C levels at baseline and more impor-
tant, in the achieved target levels. The study furthermore 
indicates the capacity of intensified lipid lowering ther-
apy versus previous standard therapy applied in practice 
Fig. 2 Low density lipoprotein cholesterol levels at baseline of the study (mg/dl), illustrating the described east west gradient in 
Austria
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(up to − 42 %, additional LDL-C reduction after switch 
from baseline therapy in Vorarlberg).
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